Artificial Neural Network-Based Prediction of Multiple Sclerosis using Blood-Based Metabolomics Data
Recommended Citation
Ata N, Zahoor I, Hoda N, Adnan SM, Vijayakumar S, Louis F, Poisson L, Rattan R, Kumar N, Cerghet M, and Giri S. Artificial neural network-based prediction of multiple sclerosis using blood-based metabolomics data. Mult Scler Relat Disord 2024; 92:105942.
Document Type
Article
Publication Date
10-15-2024
Publication Title
Mult Scler Relat Disord
Abstract
Multiple sclerosis (MS) remains a challenging neurological condition for diagnosis and management and is often detected in late stages, delaying treatment. Artificial intelligence (AI) is emerging as a promising approach to extracting MS information when applied to different patient datasets. Given the critical role of metabolites in MS profiling, metabolomics data may be an ideal platform for the application of AI to predict disease. In the present study, a machine-learning (ML) approach was used for a detailed analysis of metabolite profiles and related pathways in patients with MS and healthy controls (HC). This approach identified unique alterations in biochemical metabolites and their correlation with disease severity parameters. To enhance the efficiency of using metabolic profiles to determine disease severity or the presence of MS, we trained an AI model on a large volume of blood-based metabolomics datasets. We constructed this model using an artificial neural network (ANN) architecture with perceptrons. Data were divided into training, validation, and testing sets to determine model accuracy. After training, accuracy reached 87 %, sensitivity was 82.5 %, specificity was 89 %, and precision was 77.3 %. Thus, the developed model seems highly robust, generalizable with a wide scope and can handle large amounts of data, which could potentially assist neurologists. However, a large multicenter cohort study is necessary for further validation of large-scale datasets to allow the integration of AI in clinical settings for accurate diagnosis and improved MS management.
PubMed ID
39471746
Volume
92
First Page
105942
Last Page
105942